Madrigal Pharmaceuticals (MDGL)

Executive Summary

Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company leading the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with its first-in-class thyroid hormone receptor beta agonist, Rezdiffra (resmetirom). Approved in 2024, Rezdiffra is the only therapy indicated for MASH with moderate to advanced liver fibrosis, addressing a significant unmet need in a large and growing patient population. The company is focused on commercial execution, post-marketing studies, and expanding the label to broader MASH populations. Madrigal maintains a robust pipeline, including a Phase 2/3 combination trial with other agents and a long-term Phase 3 extension study (MAESTRO-NASH). With a strong first-mover advantage, a favorable safety profile, and a dedicated sales force, Madrigal is well-positioned to capture meaningful market share and drive revenue growth. However, competitive pressures from emerging MASH therapies and the need to demonstrate long-term clinical and economic value remain key risks.

Upcoming Catalysts (preview)

• H1 2027Phase 2/3 trial of resmetirom plus placebo (NCT07335601) interim or final data70% success
• H2 2026Label expansion for Rezdiffra in earlier-stage MASH or additional subgroups60% success
• Q3 2026Quarterly commercial revenue updates and reimbursement expansion catalysts90% success